Medindia

X

Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference

Monday, September 29, 2008 General News J E 4
Advertisement
SOUTH SAN FRANCISCO, Calif., Sept. 29 PoniardPharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused ononcology, today announced that Jerry McMahon, Ph.D., chairman and CEO, willpresent at the JMP Securities Healthcare Focus Conference on Monday, October6, at 9 a.m. Eastern Time at Le Parker Meridien in New York.

Dr. McMahon will provide a corporate overview, including a discussion ofthe development of picoplatin, the Company's lead product candidate.

A live audio webcast of the presentation will be available for 10 businessdays on the "Events" page of the "News & Events" section of the Company'swebsite at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused onthe development and commercialization of innovative oncology products toimpact the lives of people with cancer. Picoplatin, the Company's leadplatform product candidate, is a new generation platinum therapy with animproved safety profile relative to existing platinum-based cancer therapies.Picoplatin is designed to overcome platinum resistance associated withchemotherapy in solid tumors, and is being studied in multiple cancerindications, combinations and formulations. Clinical trials of intravenouspicoplatin include a Phase 3 trial in small cell lung cancer and Phase 2trials in metastatic colorectal and hormone-refractory prostate cancers, aswell as a clinical trial of oral picoplatin in solid tumors. Picoplatin hasnot been approved by any regulatory authority for use in humans. Foradditional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals,Inc.

SOURCE Poniard Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Nomad Bioscience: New Plant Biotechnology Company ...
S
Poniard Pharmaceuticals to Present at the JMP Secu...